Multifunctional Antibodies Are Induced by the RTS,S Malaria Vaccine and Associated With Protection in a Phase 1/2a Trial
Abstract Background RTS,S is the leading malaria vaccine candidate but only confers partial efficacy against malaria in children. RTS,S is based on the major Plasmodium falciparum sporozoite surface antigen, circumsporozoite protein (CSP). The induction of anti-CSP antibodies is important for protec...
Saved in:
Published in | The Journal of infectious diseases Vol. 224; no. 7; pp. 1128 - 1138 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
US
Oxford University Press
13.10.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Background
RTS,S is the leading malaria vaccine candidate but only confers partial efficacy against malaria in children. RTS,S is based on the major Plasmodium falciparum sporozoite surface antigen, circumsporozoite protein (CSP). The induction of anti-CSP antibodies is important for protection; however, it is unclear how these protective antibodies function.
Methods
We quantified the induction of functional anti-CSP antibody responses in healthy malaria-naive adults (N = 45) vaccinated with RTS,S/AS01. This included the ability to mediate effector functions via the fragment crystallizable (Fc) region, such as interacting with human complement proteins and Fcγ-receptors (FcγRs) that are expressed on immune cells, which promote various immunological functions.
Results
Our major findings were (1) RTS,S-induced antibodies mediated Fc-dependent effector functions, (2) functional antibodies were generally highest after the second vaccine dose, (3) functional antibodies targeted multiple regions of CSP, (4) participants with higher levels of functional antibodies had a reduced probability of developing parasitemia following homologous challenge (P < .05), and (5) nonprotected subjects had higher levels of anti-CSP IgM.
Conclusions
Our data suggest a role for Fc-dependent antibody effector functions in RTS,S-induced immunity. Enhancing the induction of these functional activities may be a strategy to improve the protective efficacy of RTS,S or other malaria vaccines.
Clinical Trials Registration
NCT00075049
The leading malaria vaccine, RTS,S, induced antibodies that mediate various Fc-dependent effector functions. High levels of antibodies with multiple functional activities were associated with protection against homologous malaria challenge. This provides valuable insights for improving RTS,S or future malaria vaccines. |
---|---|
AbstractList | Abstract
Background
RTS,S is the leading malaria vaccine candidate but only confers partial efficacy against malaria in children. RTS,S is based on the major Plasmodium falciparum sporozoite surface antigen, circumsporozoite protein (CSP). The induction of anti-CSP antibodies is important for protection; however, it is unclear how these protective antibodies function.
Methods
We quantified the induction of functional anti-CSP antibody responses in healthy malaria-naive adults (N = 45) vaccinated with RTS,S/AS01. This included the ability to mediate effector functions via the fragment crystallizable (Fc) region, such as interacting with human complement proteins and Fcγ-receptors (FcγRs) that are expressed on immune cells, which promote various immunological functions.
Results
Our major findings were (1) RTS,S-induced antibodies mediated Fc-dependent effector functions, (2) functional antibodies were generally highest after the second vaccine dose, (3) functional antibodies targeted multiple regions of CSP, (4) participants with higher levels of functional antibodies had a reduced probability of developing parasitemia following homologous challenge (P < .05), and (5) nonprotected subjects had higher levels of anti-CSP IgM.
Conclusions
Our data suggest a role for Fc-dependent antibody effector functions in RTS,S-induced immunity. Enhancing the induction of these functional activities may be a strategy to improve the protective efficacy of RTS,S or other malaria vaccines.
Clinical Trials Registration
NCT00075049
The leading malaria vaccine, RTS,S, induced antibodies that mediate various Fc-dependent effector functions. High levels of antibodies with multiple functional activities were associated with protection against homologous malaria challenge. This provides valuable insights for improving RTS,S or future malaria vaccines. RTS,S is the leading malaria vaccine candidate but only confers partial efficacy against malaria in children. RTS,S is based on the major Plasmodium falciparum sporozoite surface antigen, circumsporozoite protein (CSP). The induction of anti-CSP antibodies is important for protection; however, it is unclear how these protective antibodies function. We quantified the induction of functional anti-CSP antibody responses in healthy malaria-naive adults (N = 45) vaccinated with RTS,S/AS01. This included the ability to mediate effector functions via the fragment crystallizable (Fc) region, such as interacting with human complement proteins and Fcγ-receptors (FcγRs) that are expressed on immune cells, which promote various immunological functions. Our major findings were (1) RTS,S-induced antibodies mediated Fc-dependent effector functions, (2) functional antibodies were generally highest after the second vaccine dose, (3) functional antibodies targeted multiple regions of CSP, (4) participants with higher levels of functional antibodies had a reduced probability of developing parasitemia following homologous challenge (P < .05), and (5) nonprotected subjects had higher levels of anti-CSP IgM. Our data suggest a role for Fc-dependent antibody effector functions in RTS,S-induced immunity. Enhancing the induction of these functional activities may be a strategy to improve the protective efficacy of RTS,S or other malaria vaccines. NCT00075049. The leading malaria vaccine, RTS,S, induced antibodies that mediate various Fc-dependent effector functions. High levels of antibodies with multiple functional activities were associated with protection against homologous malaria challenge. This provides valuable insights for improving RTS,S or future malaria vaccines. Background RTS,S is the leading malaria vaccine candidate but only confers partial efficacy against malaria in children. RTS,S is based on the major Plasmodium falciparum sporozoite surface antigen, circumsporozoite protein (CSP). The induction of anti-CSP antibodies is important for protection; however, it is unclear how these protective antibodies function. Methods We quantified the induction of functional anti-CSP antibody responses in healthy malaria-naive adults (N = 45) vaccinated with RTS,S/AS01. This included the ability to mediate effector functions via the fragment crystallizable (Fc) region, such as interacting with human complement proteins and Fcγ-receptors (FcγRs) that are expressed on immune cells, which promote various immunological functions. Results Our major findings were (1) RTS,S-induced antibodies mediated Fc-dependent effector functions, (2) functional antibodies were generally highest after the second vaccine dose, (3) functional antibodies targeted multiple regions of CSP, (4) participants with higher levels of functional antibodies had a reduced probability of developing parasitemia following homologous challenge (P < .05), and (5) nonprotected subjects had higher levels of anti-CSP IgM. Conclusions Our data suggest a role for Fc-dependent antibody effector functions in RTS,S-induced immunity. Enhancing the induction of these functional activities may be a strategy to improve the protective efficacy of RTS,S or other malaria vaccines. Clinical Trials Registration NCT00075049 RTS,S is the leading malaria vaccine candidate but only confers partial efficacy against malaria in children. RTS,S is based on the major Plasmodium falciparum sporozoite surface antigen, circumsporozoite protein (CSP). The induction of anti-CSP antibodies is important for protection; however, it is unclear how these protective antibodies function.BACKGROUNDRTS,S is the leading malaria vaccine candidate but only confers partial efficacy against malaria in children. RTS,S is based on the major Plasmodium falciparum sporozoite surface antigen, circumsporozoite protein (CSP). The induction of anti-CSP antibodies is important for protection; however, it is unclear how these protective antibodies function.We quantified the induction of functional anti-CSP antibody responses in healthy malaria-naive adults (N = 45) vaccinated with RTS,S/AS01. This included the ability to mediate effector functions via the fragment crystallizable (Fc) region, such as interacting with human complement proteins and Fcγ-receptors (FcγRs) that are expressed on immune cells, which promote various immunological functions.METHODSWe quantified the induction of functional anti-CSP antibody responses in healthy malaria-naive adults (N = 45) vaccinated with RTS,S/AS01. This included the ability to mediate effector functions via the fragment crystallizable (Fc) region, such as interacting with human complement proteins and Fcγ-receptors (FcγRs) that are expressed on immune cells, which promote various immunological functions.Our major findings were (1) RTS,S-induced antibodies mediated Fc-dependent effector functions, (2) functional antibodies were generally highest after the second vaccine dose, (3) functional antibodies targeted multiple regions of CSP, (4) participants with higher levels of functional antibodies had a reduced probability of developing parasitemia following homologous challenge (P < .05), and (5) nonprotected subjects had higher levels of anti-CSP IgM.RESULTSOur major findings were (1) RTS,S-induced antibodies mediated Fc-dependent effector functions, (2) functional antibodies were generally highest after the second vaccine dose, (3) functional antibodies targeted multiple regions of CSP, (4) participants with higher levels of functional antibodies had a reduced probability of developing parasitemia following homologous challenge (P < .05), and (5) nonprotected subjects had higher levels of anti-CSP IgM.Our data suggest a role for Fc-dependent antibody effector functions in RTS,S-induced immunity. Enhancing the induction of these functional activities may be a strategy to improve the protective efficacy of RTS,S or other malaria vaccines.CONCLUSIONSOur data suggest a role for Fc-dependent antibody effector functions in RTS,S-induced immunity. Enhancing the induction of these functional activities may be a strategy to improve the protective efficacy of RTS,S or other malaria vaccines.NCT00075049.CLINICAL TRIALS REGISTRATIONNCT00075049. |
Author | Boyle, Michelle J Drew, Damien R Bergmann-Leitner, Elke S Atre, Tanmaya Chan, Jo-Anne Beeson, James G Fowkes, Freya J I Kurtovic, Liriye Feng, Gaoqian Wines, Bruce D Hogarth, P Mark |
AuthorAffiliation | 5 Department of Clinical Pathology, University of Melbourne, Melbourne, Australia 6 QIMR Berghofer , Herston, Australia 9 Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne , Melbourne, Australia 2 Department of Immunology and Pathology, Monash University, Melbourne, Australia 4 Department of Medicine, University of Melbourne , Parkville, Australia 8 Department of Infectious Diseases, Monash University , Melbourne, Australia 7 Department of Epidemiology and Preventative Medicine, Monash University , Melbourne, Australia 1 Burnet Institute, Melbourne, Australia 3 Malaria Vaccine Branch, US Military Malaria Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA 10 Department of Microbiology, Monash University , Clayton, Australia |
AuthorAffiliation_xml | – name: 7 Department of Epidemiology and Preventative Medicine, Monash University , Melbourne, Australia – name: 2 Department of Immunology and Pathology, Monash University, Melbourne, Australia – name: 6 QIMR Berghofer , Herston, Australia – name: 8 Department of Infectious Diseases, Monash University , Melbourne, Australia – name: 9 Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne , Melbourne, Australia – name: 4 Department of Medicine, University of Melbourne , Parkville, Australia – name: 3 Malaria Vaccine Branch, US Military Malaria Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA – name: 1 Burnet Institute, Melbourne, Australia – name: 10 Department of Microbiology, Monash University , Clayton, Australia – name: 5 Department of Clinical Pathology, University of Melbourne, Melbourne, Australia |
Author_xml | – sequence: 1 givenname: Liriye surname: Kurtovic fullname: Kurtovic, Liriye organization: Burnet Institute, Melbourne, Australia – sequence: 2 givenname: Tanmaya surname: Atre fullname: Atre, Tanmaya organization: Malaria Vaccine Branch, US Military Malaria Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA – sequence: 3 givenname: Gaoqian surname: Feng fullname: Feng, Gaoqian organization: Burnet Institute, Melbourne, Australia – sequence: 4 givenname: Bruce D surname: Wines fullname: Wines, Bruce D organization: Burnet Institute, Melbourne, Australia – sequence: 5 givenname: Jo-Anne surname: Chan fullname: Chan, Jo-Anne organization: Burnet Institute, Melbourne, Australia – sequence: 6 givenname: Michelle J surname: Boyle fullname: Boyle, Michelle J organization: Burnet Institute, Melbourne, Australia – sequence: 7 givenname: Damien R surname: Drew fullname: Drew, Damien R organization: Burnet Institute, Melbourne, Australia – sequence: 8 givenname: P Mark surname: Hogarth fullname: Hogarth, P Mark organization: Burnet Institute, Melbourne, Australia – sequence: 9 givenname: Freya J I surname: Fowkes fullname: Fowkes, Freya J I organization: Burnet Institute, Melbourne, Australia – sequence: 10 givenname: Elke S surname: Bergmann-Leitner fullname: Bergmann-Leitner, Elke S organization: Malaria Vaccine Branch, US Military Malaria Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA – sequence: 11 givenname: James G orcidid: 0000-0002-1018-7898 surname: Beeson fullname: Beeson, James G email: beeson@burnet.edu.au organization: Burnet Institute, Melbourne, Australia |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32236404$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkc1rVDEUxYNU7LS6dSkBNwqdTvKSvJe3EYbiR6HFYkddhkxy42R4k4xJntj_3rQzFS2Ii8td3N85HO45QgchBkDoOSWnlPRs5oOzPs_WXmvK-SM0oYJ107al7ABNCGmaKZV9f4iOcl4TQjhruyfokDUNaznhE_TzchyKd2MwxcegBzwPxS-j9ZDxPAE-D3Y0YPHyBpcV4E-L65NrfKkHnbzGX7QxPgDWweJ5ztF4XSr71ZcVvkqxwJ0p9gFrfLXSGTCdNRovqnZ4ih47PWR4tt_H6PO7t4uzD9OLj-_Pz-YXU8NFU6adFY0w3AC3jPWUcuuI5s4KtpQCmGCNIcQ5JxzvwHQMZD0yWoe1zHLGjtGbne92XG7AGggl6UFtk9_odKOi9urvS_Ar9S3-UFJQTiWtBq_2Bil-HyEXtfHZwDDoAHHMqmFSdERSTir68gG6jmOqX62U6DvJZS_bSr34M9HvKPelVIDvAJNizgmcMr7o21fWgH5QlKjb7tWue7XvvspOH8junf8peL0TxHH7P_YXbBjCXQ |
CitedBy_id | crossref_primary_10_1016_j_lanmic_2024_101001 crossref_primary_10_1080_21645515_2021_1985891 crossref_primary_10_1080_21505594_2022_2150456 crossref_primary_10_1016_j_ijpharm_2024_124746 crossref_primary_10_1016_j_vaccine_2020_09_069 crossref_primary_10_1093_cid_ciab1017 crossref_primary_10_1080_14760584_2023_2274479 crossref_primary_10_1016_j_medj_2021_10_003 crossref_primary_10_1080_14760584_2021_1882309 crossref_primary_10_1016_j_pt_2022_08_013 crossref_primary_10_1038_s41591_023_02659_z crossref_primary_10_1080_14728222_2021_1907343 crossref_primary_10_1128_spectrum_03791_22 crossref_primary_10_1016_j_ijpara_2021_01_006 crossref_primary_10_1186_s11671_023_03849_x crossref_primary_10_1186_s12936_023_04549_8 crossref_primary_10_1016_S2666_5247_24_00130_7 crossref_primary_10_1038_s41467_021_22236_7 crossref_primary_10_1002_cti2_70005 crossref_primary_10_3389_fimmu_2021_683404 crossref_primary_10_1016_j_molimm_2022_08_017 crossref_primary_10_1186_s12916_024_03604_8 crossref_primary_10_3389_fimmu_2023_1183727 crossref_primary_10_1093_infdis_jiad115 crossref_primary_10_1172_JCI169060 crossref_primary_10_1111_imcb_12415 crossref_primary_10_1186_s13071_023_06071_x crossref_primary_10_1186_s12916_022_02466_2 crossref_primary_10_1186_s12936_024_04846_w crossref_primary_10_1080_14760584_2021_1981864 crossref_primary_10_1038_s41541_025_01078_0 crossref_primary_10_1038_s41467_024_51701_2 crossref_primary_10_1084_jem_20200942 |
Cites_doi | 10.1371/journal.pone.0111020 10.1002/jlb.49.6.556 10.1186/s12916-018-1186-4 10.1016/j.vaccine.2007.07.010 10.1056/NEJMoa1515257 10.1086/600120 10.1128/JVI.00700-17 10.1371/journal.pone.0001278 10.4049/jimmunol.143.5.1716 10.1056/NEJMoa1505819 10.1016/S0264-410X(02)00770-3 10.1128/JVI.00285-16 10.1126/sciadv.aax4489 10.30875/f309483f-en 10.1186/1475-2875-12-11 10.3389/fimmu.2017.00280 10.1186/s12916-018-1054-2 10.1128/IAI.00920-17 10.1371/journal.pmed.1001685 10.1086/656190 10.1016/j.vaccine.2007.05.005 10.1016/S0140-6736(04)17223-1 10.1046/j.1365-3024.2003.00495.x 10.1186/s12936-016-1596-8 10.1016/S1473-3099(15)00239-X 10.1038/s41467-019-10195-z 10.1186/s12916-019-1277-x 10.1126/scitranslmed.3007730 10.3389/fimmu.2015.00262 10.1016/j.vaccine.2010.05.033 10.1038/s41467-019-08528-z 10.1086/318534 10.1186/s12936-016-1348-9 10.1056/NEJMoa1102287 10.4049/jimmunol.132.2.909 10.1126/scitranslmed.aau1458 10.1016/S0140-6736(15)60721-8 10.1093/infdis/jiw237 10.1371/journal.pone.0025786 10.1016/S1473-3099(11)70100-1 10.1080/21645515.2018.1442996 10.1016/S0140-6736(07)61542-6 10.1371/journal.pone.0007302 10.4161/hv.6.1.9677 10.1189/jlb.0313144 10.1128/IAI.00533-10 10.4049/jimmunol.1602161 10.4049/jimmunol.1502551 |
ContentType | Journal Article |
Copyright | The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. 2020 The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. |
Copyright_xml | – notice: The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. 2020 – notice: The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. |
DBID | TOX AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 5PM |
DOI | 10.1093/infdis/jiaa144 |
DatabaseName | Oxford Journals Open Access Collection CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitleList | MEDLINE ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1537-6613 |
EndPage | 1138 |
ExternalDocumentID | PMC8514181 32236404 10_1093_infdis_jiaa144 10.1093/infdis/jiaa144 |
Genre | Clinical Trial, Phase II Clinical Trial, Phase I Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: ; |
GroupedDBID | --- -DZ -~X ..I .2P .55 .GJ .I3 .XZ .ZR 08P 0R~ 123 1KJ 1TH 29K 2AX 2WC 36B 3O- 4.4 41~ 48X 53G 5GY 5RE 5VS 5WD 6.Y 70D 85S AABZA AACGO AACZT AAHBH AAHTB AAJKP AAJQQ AAMVS AANCE AAOGV AAPGJ AAPNW AAPQZ AAPXW AAQQT AARHZ AASNB AAUAY AAUQX AAVAP AAWDT AAWTL AAYOK ABBHK ABEUO ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPEJ ABPLY ABPPZ ABPTD ABQLI ABQNK ABSAR ABSMQ ABTLG ABWST ABXSQ ABXVV ABZBJ ACFRR ACGFO ACGFS ACGOD ACMRT ACPQN ACPRK ACUFI ACUTJ ACUTO ACYHN ACZBC ADACV ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKPW AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFHKK AFIYH AFOFC AFSHK AFXAL AFXEN AFYAG AGINJ AGKEF AGKRT AGMDO AGQXC AGSYK AGUTN AHMBA AHXPO AI. AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APJGH APWMN AQDSO AQKUS AQVQM ATGXG AVNTJ AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BR6 BTRTY BVRKM BZKNY C45 CDBKE CS3 CZ4 D-I DAKXR DCCCD DIK DILTD DOOOF DU5 D~K EBS ECGQY EE~ EIHJH EJD EMOBN ENERS ESX F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK G8K GAUVT GJXCC GX1 H13 H5~ HAR HQ3 HTVGU HW0 HZ~ IH2 IOX IPSME J21 J5H JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JSODD JST KAQDR KBUDW KOP KQ8 KSI KSN L7B LSO LU7 M49 MBLQV MHKGH MJL ML0 MVM N4W N9A NEJ NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P0- P2P PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TOX TR2 VH1 W2D W8F WH7 X7H X7M Y6R YAYTL YKOAZ YXANX ZE2 ZGI ZKG ZXP ~91 AAYXX ABDFA ABEJV ABGNP ABPQP ABVGC ADNBA AEMQT AGORE AHGBF AHMMS AJBYB AJNCP ALXQX CITATION JXSIZ CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 5PM |
ID | FETCH-LOGICAL-c452t-7d525c4ce4d339114df0a4fd53b85e3532c00fff5f47ec73e84fd31fd3363d433 |
IEDL.DBID | TOX |
ISSN | 0022-1899 1537-6613 |
IngestDate | Thu Aug 21 17:52:35 EDT 2025 Fri Jul 11 04:41:59 EDT 2025 Mon Jun 30 10:36:24 EDT 2025 Mon Jul 21 06:03:03 EDT 2025 Tue Jul 01 01:31:22 EDT 2025 Thu Apr 24 22:53:17 EDT 2025 Wed Aug 28 03:17:06 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | circumsporozoite protein opsonic phagocytosis vaccines antibodies Fcγ-receptor complement malaria Plasmodium falciparum |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com https://creativecommons.org/licenses/by-nc-nd/4.0 The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c452t-7d525c4ce4d339114df0a4fd53b85e3532c00fff5f47ec73e84fd31fd3363d433 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0002-1018-7898 |
OpenAccessLink | https://dx.doi.org/10.1093/infdis/jiaa144 |
PMID | 32236404 |
PQID | 2597848986 |
PQPubID | 41591 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8514181 proquest_miscellaneous_2385708140 proquest_journals_2597848986 pubmed_primary_32236404 crossref_citationtrail_10_1093_infdis_jiaa144 crossref_primary_10_1093_infdis_jiaa144 oup_primary_10_1093_infdis_jiaa144 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-10-13 |
PublicationDateYYYYMMDD | 2021-10-13 |
PublicationDate_xml | – month: 10 year: 2021 text: 2021-10-13 day: 13 |
PublicationDecade | 2020 |
PublicationPlace | US |
PublicationPlace_xml | – name: US – name: United States – name: Oxford |
PublicationTitle | The Journal of infectious diseases |
PublicationTitleAlternate | J Infect Dis |
PublicationYear | 2021 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Mahajan (2021101318473275400_CIT0024) 2010; 78 Ubillos (2021101318473275400_CIT0050) 2018; 16 Hollingdale (2021101318473275400_CIT0023) 1984; 132 Kester (2021101318473275400_CIT0038) 2007; 25 Kristensen (2021101318473275400_CIT0044) 2016; 90 Okitsu (2021101318473275400_CIT0022) 2007; 2 Kurtovic (2021101318473275400_CIT0027) 2019; 17 Owusu-Agyei (2021101318473275400_CIT0039) 2009; 4 Fleit (2021101318473275400_CIT0043) 1991; 49 Cohen (2021101318473275400_CIT0014) 2010; 6 Seguin (2021101318473275400_CIT0048) 1989; 143 White (2021101318473275400_CIT0017) 2015; 15 Rosales (2021101318473275400_CIT0021) 2017; 8 Radin (2021101318473275400_CIT0049) 2016; 15 Behet (2021101318473275400_CIT0025) 2018; 86 Wines (2021101318473275400_CIT0028) 2016; 197 McLean (2021101318473275400_CIT0029) 2017; 199 Boyle (2021101318473275400_CIT0033) 2019; 5 Dobaño (2021101318473275400_CIT0019) 2019; 10 Madhavi (2021101318473275400_CIT0045) 2017; 91 Valéa (2021101318473275400_CIT0013) 2018; 14 Casares (2021101318473275400_CIT0015) 2010; 28 Li X- (2021101318473275400_CIT0046) 2016; 37 Schwenk (2021101318473275400_CIT0034) 2003; 25 Schwenk (2021101318473275400_CIT0031) 2014; 9 Kester (2021101318473275400_CIT0030) 2009; 200 Asante (2021101318473275400_CIT0041) 2011; 11 Beeson (2021101318473275400_CIT0009) 2019; 11 Jefferson (2021101318473275400_CIT0006) 2003; 21 Agnandji (2021101318473275400_CIT0012) 2010; 202 World Health Organization (2021101318473275400_CIT0001) 2018 Merle (2021101318473275400_CIT0020) 2015; 6 RTSS Clinical Trial Partnerships (2021101318473275400_CIT0004) 2015; 386 Aponte (2021101318473275400_CIT0010) 2007; 370 Ikarashi (2021101318473275400_CIT0047) 2013; 94 Kester (2021101318473275400_CIT0037) 2001; 183 Yates (2021101318473275400_CIT0036) 2014; 6 Chaudhury (2021101318473275400_CIT0035) 2016; 15 Reiling (2021101318473275400_CIT0032) 2019; 10 Alonso (2021101318473275400_CIT0018) 2004; 364 RTSS Clinical Trials Partnership (2021101318473275400_CIT0005) 2014; 11 Bayer (2021101318473275400_CIT0007) 2007; 25 Abdulla (2021101318473275400_CIT0011) 2013; 12 Olotu (2021101318473275400_CIT0003) 2016; 374 Regules (2021101318473275400_CIT0040) 2016; 214 Olotu (2021101318473275400_CIT0016) 2011; 6 Kurtovic (2021101318473275400_CIT0026) 2018; 16 Neafsey (2021101318473275400_CIT0042) 2015; 373 RTS,S Clinical Trials Partnership (2021101318473275400_CIT0002) 2011; 365 Malaria Funding Partners (2021101318473275400_CIT0008) 2013 |
References_xml | – volume: 9 start-page: e111020 year: 2014 ident: 2021101318473275400_CIT0031 article-title: IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice publication-title: PLoS One doi: 10.1371/journal.pone.0111020 – volume: 49 start-page: 556 year: 1991 ident: 2021101318473275400_CIT0043 article-title: The human monocyte-like cell line THP-1 expresses FcγRI and FCγRII publication-title: J Leukoc Biol doi: 10.1002/jlb.49.6.556 – volume: 16 start-page: 197 year: 2018 ident: 2021101318473275400_CIT0050 article-title: Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children publication-title: BMC Med doi: 10.1186/s12916-018-1186-4 – volume: 25 start-page: 6655 year: 2007 ident: 2021101318473275400_CIT0007 article-title: Metaanalysis of vaccine effectiveness in varicella outbreaks publication-title: Vaccine doi: 10.1016/j.vaccine.2007.07.010 – volume: 374 start-page: 2519 year: 2016 ident: 2021101318473275400_CIT0003 article-title: Seven-year efficacy of RTS,S/AS01 malaria vaccine among young African children publication-title: N Engl J Med doi: 10.1056/NEJMoa1515257 – volume: 200 start-page: 337 year: 2009 ident: 2021101318473275400_CIT0030 article-title: Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection publication-title: J Infect Dis doi: 10.1086/600120 – volume: 91 start-page: e00700 year: 2017 ident: 2021101318473275400_CIT0045 article-title: HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV publication-title: J Virol doi: 10.1128/JVI.00700-17 – volume: 2 start-page: e1278 year: 2007 ident: 2021101318473275400_CIT0022 article-title: A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial publication-title: PloS One doi: 10.1371/journal.pone.0001278 – volume: 143 start-page: 1716 year: 1989 ident: 2021101318473275400_CIT0048 article-title: Interactions of Plasmodium berghei sporozoites and murine Kupffer cells in vitro publication-title: J Immunol doi: 10.4049/jimmunol.143.5.1716 – volume: 373 start-page: 2025 year: 2015 ident: 2021101318473275400_CIT0042 article-title: Genetic diversity and protective efficacy of the RTS,S/AS01 malaria vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa1505819 – volume: 21 start-page: 2003 year: 2003 ident: 2021101318473275400_CIT0006 article-title: Systematic review of the effects of pertussis vaccines in children publication-title: Vaccine doi: 10.1016/S0264-410X(02)00770-3 – volume: 90 start-page: 5724 year: 2016 ident: 2021101318473275400_CIT0044 article-title: Antibody responses with Fc-mediated functions after vaccination of HIV-infected subjects with trivalent influenza vaccine publication-title: J Virol doi: 10.1128/JVI.00285-16 – volume: 5 start-page: eaax4489 year: 2019 ident: 2021101318473275400_CIT0033 article-title: IgM in human immunity to Plasmodium falciparum malaria publication-title: Sci Adv doi: 10.1126/sciadv.aax4489 – volume-title: World malaria report 2018 year: 2018 ident: 2021101318473275400_CIT0001 doi: 10.30875/f309483f-en – volume: 12 start-page: 11 year: 2013 ident: 2021101318473275400_CIT0011 article-title: Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02 D malaria vaccine in infants living in a malaria-endemic region publication-title: Malar J doi: 10.1186/1475-2875-12-11 – volume: 8 start-page: 280 year: 2017 ident: 2021101318473275400_CIT0021 article-title: Fcγ receptor heterogeneity in leukocyte functional responses publication-title: Front Immunol doi: 10.3389/fimmu.2017.00280 – volume: 16 start-page: 61 year: 2018 ident: 2021101318473275400_CIT0026 article-title: Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children publication-title: BMC Med doi: 10.1186/s12916-018-1054-2 – volume: 86 start-page: e00920-17 year: 2018 ident: 2021101318473275400_CIT0025 article-title: The complement system contributes to functional antibody-mediated responses induced by immunization with Plasmodium falciparum malaria sporozoites publication-title: Infect Immun doi: 10.1128/IAI.00920-17 – volume: 11 start-page: e1001685 year: 2014 ident: 2021101318473275400_CIT0005 article-title: Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites publication-title: PLoS Med doi: 10.1371/journal.pmed.1001685 – volume: 202 start-page: 1076 year: 2010 ident: 2021101318473275400_CIT0012 article-title: Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization publication-title: J Infect Dis doi: 10.1086/656190 – volume: 25 start-page: 5359 year: 2007 ident: 2021101318473275400_CIT0038 article-title: A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults publication-title: Vaccine doi: 10.1016/j.vaccine.2007.05.005 – volume: 364 start-page: 1411 year: 2004 ident: 2021101318473275400_CIT0018 article-title: Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(04)17223-1 – volume: 25 start-page: 17 year: 2003 ident: 2021101318473275400_CIT0034 article-title: Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine publication-title: Parasite Immunol doi: 10.1046/j.1365-3024.2003.00495.x – volume: 15 start-page: 543 year: 2016 ident: 2021101318473275400_CIT0049 article-title: A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum publication-title: Malar J doi: 10.1186/s12936-016-1596-8 – volume: 15 start-page: 1450 year: 2015 ident: 2021101318473275400_CIT0017 article-title: Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(15)00239-X – volume: 10 start-page: 2174 year: 2019 ident: 2021101318473275400_CIT0019 article-title: Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy publication-title: Nat Commun doi: 10.1038/s41467-019-10195-z – volume: 17 start-page: 45 year: 2019 ident: 2021101318473275400_CIT0027 article-title: Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure publication-title: BMC Med doi: 10.1186/s12916-019-1277-x – volume: 6 start-page: 228ra39 year: 2014 ident: 2021101318473275400_CIT0036 article-title: Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3007730 – volume: 6 start-page: 262 year: 2015 ident: 2021101318473275400_CIT0020 article-title: Complement system part I - molecular mechanisms of activation and regulation publication-title: Front Immunol doi: 10.3389/fimmu.2015.00262 – volume: 37 start-page: 1465 year: 2016 ident: 2021101318473275400_CIT0046 article-title: Effect of CD16a, the surface receptor of Kupffer cells, on the growth of hepatocellular carcinoma cells publication-title: Int J Parasitol – volume: 28 start-page: 4880 year: 2010 ident: 2021101318473275400_CIT0015 article-title: The RTS,S malaria vaccine publication-title: Vaccine doi: 10.1016/j.vaccine.2010.05.033 – volume: 10 start-page: 610 year: 2019 ident: 2021101318473275400_CIT0032 article-title: Targets of complement-fixing antibodies in protective immunity against malaria in children publication-title: Nat Commun doi: 10.1038/s41467-019-08528-z – volume: 183 start-page: 640 year: 2001 ident: 2021101318473275400_CIT0037 article-title: Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria publication-title: J Infect Dis doi: 10.1086/318534 – volume: 15 start-page: 301 year: 2016 ident: 2021101318473275400_CIT0035 article-title: The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity publication-title: Malar J doi: 10.1186/s12936-016-1348-9 – volume: 365 start-page: 1863 year: 2011 ident: 2021101318473275400_CIT0002 article-title: First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children publication-title: N Engl J Med doi: 10.1056/NEJMoa1102287 – volume: 132 start-page: 909 year: 1984 ident: 2021101318473275400_CIT0023 article-title: Inhibition of entry of Plasmodium falciparum and P. vivax publication-title: J Immunol doi: 10.4049/jimmunol.132.2.909 – volume: 11 start-page: eaau1458 year: 2019 ident: 2021101318473275400_CIT0009 article-title: Challenges and strategies for developing efficacious and long-lasting malaria vaccines publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aau1458 – volume: 386 start-page: 31 year: 2015 ident: 2021101318473275400_CIT0004 article-title: Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(15)60721-8 – volume: 214 start-page: 762 year: 2016 ident: 2021101318473275400_CIT0040 article-title: Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study publication-title: J Infect Dis doi: 10.1093/infdis/jiw237 – volume: 6 start-page: e25786 year: 2011 ident: 2021101318473275400_CIT0016 article-title: Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01 E and protection against P falciparum clinical malaria publication-title: PLoS One doi: 10.1371/journal.pone.0025786 – volume: 11 start-page: 741 year: 2011 ident: 2021101318473275400_CIT0041 article-title: Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(11)70100-1 – volume: 14 start-page: 1489 year: 2018 ident: 2021101318473275400_CIT0013 article-title: Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: a randomized controlled trial publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2018.1442996 – volume: 370 start-page: 1543 year: 2007 ident: 2021101318473275400_CIT0010 article-title: Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial publication-title: Lancet doi: 10.1016/S0140-6736(07)61542-6 – volume: 4 start-page: e7302 year: 2009 ident: 2021101318473275400_CIT0039 article-title: Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children publication-title: PLoS One doi: 10.1371/journal.pone.0007302 – volume-title: Malaria vaccine technology roadmap year: 2013 ident: 2021101318473275400_CIT0008 – volume: 6 start-page: 90 year: 2010 ident: 2021101318473275400_CIT0014 article-title: From the circumsporozoite protein to the RTS,S/AS candidate vaccine publication-title: Hum Vaccin doi: 10.4161/hv.6.1.9677 – volume: 94 start-page: 1325 year: 2013 ident: 2021101318473275400_CIT0047 article-title: Distinct development and functions of resident and recruited liver Kupffer cells/macrophages publication-title: J Leukoc Biol doi: 10.1189/jlb.0313144 – volume: 78 start-page: 4613 year: 2010 ident: 2021101318473275400_CIT0024 article-title: Multiple antigen peptide vaccines against Plasmodium falciparum malaria publication-title: Infect Immun doi: 10.1128/IAI.00533-10 – volume: 199 start-page: 816 year: 2017 ident: 2021101318473275400_CIT0029 article-title: Dimeric Fcγ receptor enzyme-linked immunosorbent assay to study HIV-specific antibodies: A new look into breadth of Fcγ receptor antibodies induced by the RV144 vaccine trial publication-title: J Immunol doi: 10.4049/jimmunol.1602161 – volume: 197 start-page: 1507 year: 2016 ident: 2021101318473275400_CIT0028 article-title: Dimeric FcγR ectodomains as probes of the Fc receptor function of anti-influenza virus IgG publication-title: J Immunol doi: 10.4049/jimmunol.1502551 |
SSID | ssj0004367 |
Score | 2.5328746 |
Snippet | Abstract
Background
RTS,S is the leading malaria vaccine candidate but only confers partial efficacy against malaria in children. RTS,S is based on the major... RTS,S is the leading malaria vaccine candidate but only confers partial efficacy against malaria in children. RTS,S is based on the major Plasmodium falciparum... Background RTS,S is the leading malaria vaccine candidate but only confers partial efficacy against malaria in children. RTS,S is based on the major Plasmodium... The leading malaria vaccine, RTS,S, induced antibodies that mediate various Fc-dependent effector functions. High levels of antibodies with multiple functional... |
SourceID | pubmedcentral proquest pubmed crossref oup |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1128 |
SubjectTerms | Antibodies Antibodies, Protozoan - blood Antigens, Protozoan Circumsporozoite protein Clinical trials Humans Immunoglobulin M Major and Brief Reports Malaria Malaria - blood Malaria - prevention & control Malaria Vaccines - administration & dosage Malaria Vaccines - immunology Parasitemia Plasmodium falciparum Protozoan Proteins Vaccine Efficacy Vaccines |
Title | Multifunctional Antibodies Are Induced by the RTS,S Malaria Vaccine and Associated With Protection in a Phase 1/2a Trial |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32236404 https://www.proquest.com/docview/2597848986 https://www.proquest.com/docview/2385708140 https://pubmed.ncbi.nlm.nih.gov/PMC8514181 |
Volume | 224 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swEBejsLGXsXVbl_WD2xj0pSa272Qrj6Ws9INsZU3bvBlZkonLcEbjQPvf9xQ7XlNatgc_6SQbn3T3O530OyG-hblmGGA4UlVJGJDK2Q6qQRQw0jdE2vIi8VsDwx_J0QWdjOW4JYuePZHCH2Cf_7QtZ_3rUmtG_2xt2QN7lvzRz_HfG5CYpEte8IhDiI6e8XH3FfezcqXtAbJ8fEDygcc5fCvetFAR9hvdvhMvXLUuXjbFI-_WxathmxZ_L24X12i9i2p29mC_qst86g8IcncHvj6HcRbyO2C8B79G53vnMNQc1JYaLrXxo4CuLCyVxbJXZT2Bs4bFgQeFsgINZxN2ehD1Yw0jP3M_iIvD76ODo6AtqRAYknEdpFbG0pBxZBHZzpEtQk2FlZgr6VBibMKwKApZUOpMik5xI0b8YIKWED-KtWpauU8CpJNGOpJsFRyRSwaFKtjbp2lO3CuKeiJY_unMtHzjvuzF76zJe2PWaCZrNdMTu538n4Zp41nJr6y4fwptLfWatctylnGslypSA5X0xJeumReUz5Loyk3nLIOe898TgfXERjMNulex9cOEQh48XZkgnYAn615tqcrJgrSbkS0xmvr8P9--KV7H_uiMPziDW2Ktvpm7bcY-db7DqP_4dGcx-e8BCB4DmA |
linkProvider | Oxford University Press |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multifunctional+Antibodies+Are+Induced+by+the+RTS%2CS+Malaria+Vaccine+and+Associated+With+Protection+in+a+Phase+1%2F2a+Trial&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Kurtovic%2C+Liriye&rft.au=Atre%2C+Tanmaya&rft.au=Feng%2C+Gaoqian&rft.au=Wines%2C+Bruce+D&rft.date=2021-10-13&rft.pub=Oxford+University+Press&rft.issn=0022-1899&rft.eissn=1537-6613&rft.volume=224&rft.issue=7&rft.spage=1128&rft.epage=1138&rft_id=info:doi/10.1093%2Finfdis%2Fjiaa144&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon |